Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Trial of ATN-224 in Combination With Temozolomide or Temozolomide Followed by ATN-224 in Patients With Advanced Melanoma

NCT00383851 is registered in ClinicalTrials.gov with Attenuon as lead sponsor.

NCT NCT00383851
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00383851 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Trial of ATN-224 in Combination With Temozolomide or Temozolomide Followed by ATN-224 in Patients With Advanced Melanoma
Lead sponsor
Attenuon
Phase
Phase 2
Overall status
Unknown status
Start date
September 30, 2006
Completion date
September 30, 2008
Enrollment
60 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma